D.A. Davidson & CO. bought a new position in shares of Horizon Pharma PLC (NASDAQ:HZNP) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,085 shares of the biopharmaceutical company’s stock, valued at approximately $143,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. BlueCrest Capital Management Ltd acquired a new stake in Horizon Pharma during the 4th quarter worth approximately $160,000. K2 Principal Fund L.P. increased its position in Horizon Pharma by 126.1% during the 4th quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 53,574 shares in the last quarter. Zeke Capital Advisors LLC acquired a new stake in Horizon Pharma during the 4th quarter worth approximately $167,000. Investors Research Corp acquired a new stake in Horizon Pharma during the 4th quarter worth approximately $174,000. Finally, Macquarie Group Ltd. increased its position in Horizon Pharma by 207.1% during the 4th quarter. Macquarie Group Ltd. now owns 12,900 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 8,700 shares in the last quarter. 84.33% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:HZNP opened at $15.01 on Tuesday. The company has a debt-to-equity ratio of 2.17, a current ratio of 1.56 and a quick ratio of 1.50. Horizon Pharma PLC has a 52-week low of $9.90 and a 52-week high of $16.02. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.89 and a beta of 1.29.
A number of analysts recently issued reports on HZNP shares. Piper Jaffray Companies reissued a “buy” rating and set a $22.00 target price on shares of Horizon Pharma in a research report on Thursday, March 1st. BidaskClub raised shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. Morgan Stanley increased their target price on shares of Horizon Pharma from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Friday, March 2nd. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, April 15th. Finally, Cowen reissued a “buy” rating and set a $24.00 target price on shares of Horizon Pharma in a research report on Thursday, March 1st. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Horizon Pharma has an average rating of “Buy” and an average price target of $19.20.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.